Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function

doi:10.1016/S0167-5699(05)80017-9

Immunology Today

Volume 12, Issue 3, 1991, Pages A58-A61

https://doi.org/10.1016/S0167-5699(05)80017-9 Get rights and content

It has been a surprise to find that the two distinct subsets of mouse CD4⁺ T cells identified from clones cultured in vitro also occur during Leishmania infection. The spectrum of disease encountered during these infections ranges from successful resolution to fatal dissemination and in mice these outcomes are accompanied by expansion of T_H1 or T_H2 CD4⁺ cells, respectively. This review focuses on the mechanisms that cause such disparate responses to the parasite.

References (41)

LiewF.Y.
Immunol. Today
(1989)
BogdanC. et al.
Parasitol Today
(1990)
SadickM.D.
J. Immunol.
(1986)
HeinzelF.P.
J. Exp. Med.
(1989)
HowardJ.G. et al.
J. Exp. Med.
(1981)
TitusR.G.
J. Immunol.
(1985)
SadickM.D.
J. Exp. Med.
(1990)
BelosevicM.
J. Immunol.
(1989)
ScottP.
J. Exp. Med.
(1989)
ScottP. et al.
J. Immunol.
(1990)

Cited by (250)

Systems vaccinology for the design of rational vaccines against protozoan parasites
2022, System Vaccinology: The History, the Translational Challenges and the Future
Vaccine development against protozoan parasites of human and veterinary importance has been predominantly addressed by conventional methodologies. Whereas the first human recombinant vaccine against malaria has been approved, most other zoonotic parasitic diseases lacks of appropriate immunoprophylaxis. Therefore, novel strategies for antigen discovery and vaccine development are required. Advances in reverse vaccinology and genetic manipulation have contributed to the discovery of new potential targets that, together with improvements in sequencing technologies, proteomics, bioinformatics, and statistics, have opened the “omics” era into protozoan parasites. The integration of all of these advances has led to the development of systems biology, which applied to vaccinology can significantly contribute to the rational design of new vaccines. The present chapter does a comprehensive review of the advances and challenges in vaccine development, and the host-immune responses as well as the potential of systems vaccinology approaches applied to protozoan parasites of economic and zoonotic importance.
Humoral immunity in leishmaniasis – Prevention or promotion of parasite growth?
2020, Cytokine: X
Leishmaniasis can present as a “spectrum” of clinical outcomes. There is evidence that these divergent clinical outcomes are attributable to genetic differences in the human host [1] as well the species of infecting parasite [2]. The spectrum of disease has largely been described by defining the polar opposites of T cell immune responses. In the mouse model, a T_H1 immune response is associated with low numbers of Leishmania parasites in lesions, whereas a T_H2 immune response has been associated with unrestricted parasite growth. In the present work, we revisit leishmaniasis and seek to better define the clinical spectrum as a function of divergent humoral immune responses. We describe examples in human, canine, and even some murine models of leishmaniasis that reveal a direct correlation between high anti-parasite antibody responses and unrestricted parasite growth. Therefore, we propose that the spectral nature of this disease may be due to quantitative and qualitative differences in the antibodies that are produced during disease. In human visceral leishmaniasis, a decrease in anti-parasite antibody levels may actually predict disease resolution. Thus, rather than defining this disease as a simple T_H1/T_H2 dichotomy, we propose that clinical leishmaniasis depends on the degree of humoral immunity, with high IgG predicting parasite persistence. These observations have obvious implications for vaccine development in leishmaniasis, and they may extend to other diseases caused by intracellular pathogens.
Correlates of GLA family adjuvants’ activities
2018, Seminars in Immunology
Citation Excerpt :
These data indicate the importance of a potent Th1 response, rather than a Th2 or suppressive microenvironment, to protection [69]. Experimental Leishmania infection of mice has both enhanced our understanding of helper T cells during an infection and allowed dissection of the Th1/Th2 paradigm [70–72]. As such, they also provide systems with which to evaluate immune biasing by adjuvants and multiparameter flow cytometry analyses of the immune responses after immunization have indicated that the degree of protection against Leishmania infection in mice largely corresponds with the frequency of CD4T cells simultaneously producing IFNγ, IL-2 and TNF [73].
Lipopolysaccharide (LPS) is a well-defined agonist of Toll-like receptor (TLR) 4 that activates innate immune responses and influences the development of the adaptive response during infection with Gram-negative bacteria. Many years ago, Dr. Edgar Ribi separated the adjuvant activity of LPS from its toxic effects, an effort that led to the development of monophosphoryl lipid A (MPL). MPL, derived from Salmonella minnesota R595, has progressed through clinical development and is now used in various product-enabling formulations to support the generation of antigen-specific responses in several commercial and preclinical vaccines. We have generated several synthetic lipid A molecules, foremost glucopyranosyl lipid adjuvant (GLA) and second-generation lipid adjuvant (SLA), and have advanced these to clinical trial for various indications. In this review we summarize the potential and current positioning of TLR4-based adjuvant formulations in approved and emerging vaccines.
Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega
2015, Research in Veterinary Science
Citation Excerpt :
For instance, Interleukin-6 (IL-6), IL-1 and Tumor Necrosis Factor (TNF)-α are pro-inflammatory cytokines strongly involved in the innate immune response, potentiating nonspecific pathways such as acute phase response (APR) or fever (Ceron et al., 2005; Paltrinieri, 2008; Tizard, 2009a). Concerning the acquired immune pathways, IL-2, IL-12 and IFN-γ are strongly related to the cellular immune response (Th1 subset activation) (Locksley and Scott, 1991; Pedersen et al., 1998; Tizard, 2009b; VanCott et al., 1996) while the humoral antibody response (Th2 subset) is associated with IL-4, IL-5 and IL-10 production (Barnard et al., 1996; Osborne et al., 1996; Pedersen et al., 1998; Roitt and Delves, 2001; Romagnani et al., 1994). In feline medicine, particularly in FIV, several studies have been performed not only in cell cultures but also in experimentally infected cats in order to characterize the cytokine profile after infection (Dean and Pedersen, 1998; Dean et al., 1998; Kipar et al., 2004; Lawrence et al., 1995; Lerner et al., 1998; Liang et al., 2000; Linenberger and Deng, 1999; Tompkins and Tompkins, 2008; Wood et al., 2012).
This study assesses viremia, provirus and blood cytokine profile in naturally FIV-infected cats treated with two distinct protocols of interferon omega (rFeIFN-ω).
Samples from FIV-cats previously submitted to two single-arm studies were used: 7/18 received the licensed/subcutaneous protocol (SC) while 11/18 were treated orally (PO). Viremia, provirus and blood mRNA expression of interleukin (IL)-1, IL-4, IL-6, IL-10, IL-12p40, Interferon-γ and Tumor Necrosis Factor-α were monitored by Real-Time qPCR. Concurrent plasma levels of IL-6, IL-12p40 and IL-4 were assessed by ELISA.
IL-6 plasma levels decreased in the SC group (p = 0.031). IL-6 mRNA expression (p = 0.037) decreased in the PO group, albeit not sufficiently to change concurrent plasma levels. Neither viremia nor other measured cytokines changed with therapy. Proviral load increased in the SC group (p = 0.031), which can be justified by a clinically irrelevant increase of lymphocyte count.
Independently of the protocol, rFeIFN-ω seems to act on innate immunity by reducing pro-inflammatory stimulus.
Genetic mapping reveals Pou2af2/OCA-T1–dependent tuning of tuft cell differentiation and intestinal type 2 immunity
2023, Science Immunology
Adaptive immune defense prevents Bartonella persistence upon trans-placental transmission
2022, PLoS Pathogens

View all citing articles on Scopus

View full text

The Survey of Pain Attitudes: A revised version of its pediatric form
Scandinavian Journal of Pain, Volume 11, 2016, pp. 90-95
Jordi Miró, …, Mark P. Jensen
Studying Laboratory Mice – Into the Wild
Trends in Neurosciences, Volume 42, Issue 9, 2019, pp. 566-568
Julie C. Savage, Marie-Ève Tremblay
Instillation of disinfectant behind a temporary obstruction created by an inflated urinary catheter balloon improves sink drain disinfection
American Journal of Infection Control, Volume 47, Issue 12, 2019, pp. 1522-1524
Lucas D. Jones, …, Curtis J. Donskey
WHIP 2021: immunoparasitology going virtual and global
Trends in Parasitology, Volume 37, Issue 8, 2021, pp. 679-683
Conservation of wildlife
Global Perspectives on the Transmission of Zoonotic RNA Viruses from Wild Animal Species to Humans, 2023, pp. 85-88
Jayashree Seema Nandi
Ecology and evolution of RNA viruses
Global Perspectives on the Transmission of Zoonotic RNA Viruses from Wild Animal Species to Humans, 2023, pp. 81-83
Jayashree Seema Nandi

MarchT-cell subsetsHelper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function

Immunol. Today

Parasitol Today

J. Immunol.

J. Exp. Med.

J. Exp. Med.

J. Immunol.

J. Exp. Med.

J. Immunol.

J. Exp. Med.

J. Immunol.

J. Immunol.

J. Exp. Med.

J. Exp. Med.

J. Exp. Med.

J. Exp. Med.

J. Immunol.

J. Immunol.

J. Exp. Med.

Science

J. Immunol.

March
T-cell subsets
Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function